

Recommandations sur le SCA avec Sus décalage persistant du ST (ACS STEMI)

C. Abdelkhirane, MD, PhD

Barcelone, ESC, 26 août 2017

ESC 26-31 Août 2017







Diapositives

Police

Paragraphe

Insérer

Format

Diaporama

Nouvelle diapositive

Disposition

Section

Texte

Image

Forme

Média

Réorganiser

Styles rapides

Remplissage

Trait

Lecture

1 2 3 4 5 6 7 8 9 10

11 12 13 14 15 16 17 18 19 20

21 22 23 24 25 26 27 28 29 30

31 32 33 34 35 36 37 38 39 40

41 42 43 44 45 46 47 48 49 50



Diapositives

Police

Paragraphe

Insérer

Format

Diaporama

Disposition

Section

Nouvelle diapositive

Texte

Image

Forme

Média

Réorganiser

Styles rapides

Remplissage

Trait

Lecture

51 Management of hepatocarcinoma

52 Summary of indications for imaging and when testing in E1 evidence-based clinical practice guideline

53 Summary of indications for imaging and when testing in E1 evidence-based clinical practice guideline

54 Summary of indications for imaging and when testing in E1 evidence-based clinical practice guideline

55 Behavioral aspects after E1 evidence-based clinical practice guideline

56 Management antibiotic therapy after E1 evidence-based clinical practice guideline

57 Management antibiotic therapy after E1 evidence-based clinical practice guideline

58 Management antibiotic therapy after E1 evidence-based clinical practice guideline

59 Active strategies in the acute, subacute and long-term phases

60 Active strategies in the acute, subacute and long-term phases

61 Active strategies in the acute, subacute and long-term phases

62 "New liver transplantation criteria: imaging and laboratory testing"

63 "New liver transplantation criteria: imaging and laboratory testing"

64 "New liver transplantation criteria: imaging and laboratory testing"

65 "New liver transplantation criteria: imaging and laboratory testing"

66 "New liver transplantation criteria: imaging and laboratory testing"

67 "New liver transplantation criteria: imaging and laboratory testing"

68 "New liver transplantation criteria: imaging and laboratory testing"

69 Management of all metastatic dysplasias and when liver resection in E1 evidence-based clinical practice guideline

70 Management of all metastatic dysplasias and when liver resection in E1 evidence-based clinical practice guideline

71 Management of all metastatic dysplasias and when liver resection in E1 evidence-based clinical practice guideline

72 Management of colorectal adenoma in E1 evidence-based clinical practice guideline

73 Management of colorectal adenoma in E1 evidence-based clinical practice guideline

74 Management of colorectal adenoma in E1 evidence-based clinical practice guideline

75 Management of oral herpetic

76 Management of oral herpetic

77 Management of work site performance and reduction disturbances in the acute phase

78 Management of work site performance and reduction disturbances in the acute phase

79 Management of work site performance and reduction disturbances in the acute phase

80 Management of work site performance and reduction disturbances in the acute phase

81 Using team management of respiratory signs and lab assessment for quality

82 Diagnostic criteria for myocardial infarction and when testing in E1 evidence-based clinical practice guideline

83 Diagnostic criteria for myocardial infarction and when testing in E1 evidence-based clinical practice guideline

84 Diagnostic criteria for myocardial infarction and when testing in E1 evidence-based clinical practice guideline

85 Diagnostic criteria for myocardial infarction and when testing in E1 evidence-based clinical practice guideline

86 Diagnostic criteria for myocardial infarction and when testing in E1 evidence-based clinical practice guideline

87 Quality indicators

88 Quality indicators

89 Quality indicators

90 Quality indicators

91 Quality indicators

92 Quality indicators

93 Full text: E11 Pocket Guidelines App and App Store

94 E11 Pocket Guidelines App

Modifications notables dans les recommandations lors de la phase aiguë de l'infarctus du myocarde


- Sur le plan procédural (technique)
 - L'abord artériel : fémoral ou radial?
 - Le choix du stent: actif ou passif?
 - La revascularisation : L'artère responsable vs Tout?
 - La revascularisation après 48H ?
- Sur le plan médicamenteux
 - Quid de la bivaluridine?
 - HNF ou HBPM? Et Laquelle?
 - Oxygénothérapie systématique : oui ou non?
 - La fibrinolyse (tnk-tpa) : Encore?


(β -Bloquants, les P2Y12, la PCIA, Th-Aspiration)

La Radiale ,Voie reine MATRIX







Completely transferred Access for STEMI PCI





<https://doi.org/10.1161/CIRCINTERVENTIONS.114.001314>
 Circulation: Cardiovascular Interventions. 2014;7:456-464
 Originally published June 24, 2014



Stent actif prioritaire : DEDICATION Trial




Tout revasculariser?

PRAMI, DANAMI-3-PRIMULTI
CVLPRIT, Compare-Acute

Tout revasculariser oui, mais avec FFR...ou iFR



Revasculariser après 48H? Le couperet est tombé!



Recommendations for reperfusion therapy

Recommendation	Class ^a	Level ^b
Reperfusion therapy is indicated in all patients with symptoms of ischaemia of ≤ 12 h duration and persistent ST-segment elevation. ^{133,139}	I	A
A primary PCI strategy is recommended over fibrinolysis within indicated timeframes. ^{133,136,139,140}	I	A
If timely primary PCI cannot be performed after STEMI diagnosis, fibrolytic therapy is recommended within 12 h of symptom onset in patients without contraindications. ^{133,139,141}	I	A
In the absence of ST-segment elevation, a primary PCI strategy is indicated in patients with suspected ongoing ischaemic symptoms suggestive of MI and at least one of the following criteria present: <ul style="list-style-type: none"> - haemodynamic instability or cardiogenic shock - recurrent or ongoing chest pain refractory to medical treatment - life-threatening arrhythmias or cardiac arrest - mechanical complications of MI - acute heart failure - recurrent dynamic ST-segment or T-wave changes, particularly with intermittent ST-segment elevation. 	I	C
Early angiography (within 24 h) is recommended if symptoms are completely relieved and ST-segment elevation is completely normalized spontaneously or after nitroglycerin administration (provided there is no recurrence of symptoms or ST-segment elevation).	I	C
In patients with time from symptom onset >12 h, a primary PCI strategy is indicated in the presence of ongoing symptoms suggestive of ischaemia, haemodynamic instability, or other high-risk features. ^{133,142}	I	C
A routine primary PCI strategy should be considered in patients presenting late (12–48 h) after symptom onset. ^{133,134,142}	IIa	B
In asymptomatic patients, routine PCI of an occluded IRA >48 h after onset of STEMI is not indicated. ^{135,137}	III	A

IRA = infarct-related artery; MI, myocardial infarction; PCI = percutaneous coronary intervention; STEMI = ST-segment elevation myocardial infarction.

^aClass of recommendation.

^bLevel of evidence.

A routine primary PCI strategy should be considered in patients presenting late (12–48 h) after symptom onset.^{133,134,142}

IIa

B

In asymptomatic patients, routine PCI of an occluded IRA >48 h after onset of STEMI is not indicated.^{135,137}

III

A

IRA = infarct-related artery; MI, myocardial infarction; PCI = percutaneous coronary intervention; STEMI = ST-segment elevation myocardial infarction.

^aClass of recommendation.

^bLevel of evidence.



Symptoms onset 0

Early phase of STEMI

3 hours


12 hours

Evolved STEMI

48 hours


Recent STEMI

Primary PCI




I A

Fibrinolysis




(only if PCI cannot be performed within 120 min from STEMI diagnosis)

Primary PCI



I A

Fibrinolysis




(only if PCI cannot be performed within 120 min from STEMI diagnosis)

Primary PCI
(if symptoms, hemodynamic instability, or arrhythmias)



I C

Primary PCI
(asymptomatic stable patients)



Ia B

Routine PCI
(asymptomatic stable patients)



III A

Bivaluridine:
MATRIX, HEAT-PPCI

IA à IIB

Thromboaspiration de routine : TOTAL et TASTE

IIB à III

ESC Guidelines

ratio 1.56, 95% CI 1.02–2.42, $P = 0.04$]. However, the interaction P values were 0.32 and 0.34, respectively.¹⁶²

In the Taste¹⁵⁷ and TOTAL trials¹⁵⁹, 1–5% of randomized patients crossed over from PCI alone to thrombus aspiration. Based on these data and the results of a recent meta-analysis,¹⁶² routine thrombus aspiration is not recommended, but in cases of large residual thrombus burden after opening the vessel with a guide wire or a balloon, thrombus aspiration may be considered.



IIB



III

?

Héparines:

HNF : oui encore et encore...

Enoxaparine IIB à IIA

Pas les autres HBPM

Oxygénothérapie systématique: AVOID, DETO2X

Oxygen is indicated in hypoxic patients with arterial oxygen saturation (SaO_2) < 90%. There is some evidence suggesting that hyperoxia may be harmful in patients with uncomplicated MI, presumably due to increased myocardial injury.⁶⁴⁻⁶⁷ Thus, routine oxygen is not recommended when SaO_2 is $\geq 90\%$.

Relief of hypoxaemia and symptoms

Recommendations	Class	Level
Hypoxia		
Oxygen is indicated in patients with hypoxaemia (SaO ₂ <90% or PaO ₂ <60 mmHg).	I	C
Routine oxygen is not recommended in patients with SaO ₂ ≥90%.	III	B
Symptoms		
Titrated i.v. opioids should be considered to relieve pain.	IIa	C
A mild tranquillizer (usually a benzodiazepine) should be considered in very anxious patients.	IIa	C

Que retenir?

Modifications notables dans les recommandations lors de la phase aiguë de l'infarctus du myocarde

- Sur le plan procédural (technique)
 - L'abord artériel : **Radial IIA vers IA**
 - Le choix du stent: **Actif IIA vers IA**
 - La revascularisation : **Tout IIIA vers IIA**
 - La revascularisation après 48H : **IIIA**
- Sur le plan médicamenteux
 - Quid de la bivaluridine? **De IB vers IIA**
 - HNF ou HBPM? Et laquelle? **Enoxaparine IIA**
 - Oxygénothérapie systématique : **oui si SaO₂<90% IA**
 - La fibrinolyse (tnk-tpa) : **½ dose pour >75 ans**

(β-Bloquants, les P2Y₁₂,la PCIA, Th-Aspiration)

What is new in 2017 Guidelines on AMI-STEMI

2012	CHANGE IN RECOMMENDATIONS	2017
	Radial access	MATRIX
	DES over BMS	EXAMINATION, COMFORTABLE-AMI, NORSTENT
	Complete Revascularisation	PRAMI, DANAMI-3-PRIMULTI, CVLPRIT, Compare-Acute
	Thrombus Aspiration	TOTAL, TASTE
	Bivalirudin	MATRIX, HEAT-PPCI
	Enoxaparin	AT OLL, Meta-analysis
	Early Hospital Discharge	Small trials & observational data
Oxygen when SaO ₂ <95%	OXYGEN	Oxygen when SaO ₂ <90% AVOID, DETO2X
Same dose i.v. in all patients	TNK-tPA	Half dose i.v. in Pts ≥75 years STREAM

Merci